Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2022 Results Conference Call May 4, 2022 8:00 AM ET
Company Participants
Bennett Watson - Investor Relations
Keith Kendall - Chief Executive Officer
Ernie Toth - Chief Financial Officer
Daniel Barber - Chief Operating Officer
Conference Call Participants
Jason Butler - JMP Securities
Thomas Flaten - Lake Street
Andreas Argyrides - Wedbush Securities
Raghuram Selvaraju - HC Wainwright
Operator
Good day and thank you for standing by. I would now like to introduce your host for today’s call, Bennett Watson. You may begin.
Bennett Watson
Thank you, operator. Good morning and welcome to today’s call. On today’s call, I’m joined by Keith Kendall, Chief Executive Officer and Ernie Toth, Chief Financial Officer, who are going to provide an overview of recent business developments and performance in the first quarter 2022, followed by a Q&A session.
As a reminder, the Company’s remarks today correspond with the earnings release that was issued after market close yesterday. In addition, a recording of today’s call will be made available on Aquestive’s website within the Investors section shortly following the conclusion of this call.
To remind you, the Aquestive team will be discussing some non-GAAP financial measures this morning as part of its review of first quarter 2022 results. A description of these measures, along with the reconciliation to GAAP can be found in the earnings release issued yesterday, which is posted on the Investors section of Aquestive’s website.
During the call, the Company will be making Forward-Looking Statements. We remind you of the company’s Safe Harbor language as outlined in yesterday’s earnings release as well as the risks and uncertainties affecting the Company as described in the Risk Factors section and in other sections included in our annual report on Form 10-K filed with the Securities and Exchange Commission on March 8, 2022. And in our quarterly reports on Form 10-Q and current reports on form 8-K filed with the SEC.
As with any pharmaceutical company with product candidates under development and products being commercialized, there are significant risks and uncertainties with respect to the company’s business and development, regulatory approval and commercialization of its products and other matters related to operations.
The impact of the ongoing COVID-19 pandemic is highly uncertain and cannot be predicted with certainty or clarity. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as the date made.